Frequently expressed glypican‐3 as a promising novel therapeutic target for osteosarcomas
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Science"
DOI: 10.1111/cas.15521
Abstract: Osteosarcoma (OS) is the most common bone malignancy without a reliable therapeutic target. Glypican‐3 (GPC3) mutation and upregulation have been detected in multidrug resistant OS, and anti‐GPC3 immunotherapy can effectively suppress the growth of organoids.… read more here.
Keywords: therapeutic target; anti gpc3; cd133; expression ... See more keywords
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+ hepatocellular carcinoma (r/r GPC3+ HCC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.3049
Abstract: 3049Background: HCC was commonly diagnosed and identified as leading causes of cancer death in China. Using a 10% cutoff score, GPC3 was detected in 63.6% of HCCs. Safety and preliminary efficacy o... read more here.
Keywords: hcc; anti gpc3; gpc3 chimeric; study anti ... See more keywords